Keywords
Bisoprolol
Rivaroxaban
Cardiac function
Submitted : 2025-12-10
Accepted : 2025-12-25
Published : 2026-01-09
Abstract
Objective: To investigate the impact of the combined application of bisoprolol and rivaroxaban on cardiac function in patients with coronary heart disease. Methods: This study employed a retrospective design, including 90 patients diagnosed with coronary heart disease and treated in our hospital from January 2022 to June 2024. The patients were divided into a combination group (receiving both bisoprolol and rivaroxaban, n = 44) and a control group (receiving bisoprolol alone, n = 46) based on their medication regimen. Baseline data, cardiac ultrasound indicators (left ventricular ejection fraction, left ventricular end-diastolic diameter), serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, 6-minute walk test distance, and the occurrence of major adverse cardiovascular events were collected through the electronic medical record system. Results: After treatment, the left ventricular ejection fraction in the combination group was significantly higher than that in the control group (P < 0.05), and the left ventricular end-diastolic diameter in the combination group was significantly lower than that in the control group (P < 0.05). The combination group had a significantly lower NT-proBNP level compared to the control group (P < 0.05). The 6-minute walk test distance in the combination group was significantly higher than that in the control group (P < 0.05). No significant statistical difference was observed in the occurrence of major adverse cardiovascular events between the two groups (P > 0.05). Conclusion: The combined treatment of bisoprolol and rivaroxaban for patients with coronary heart disease can better improve cardiac function and enhance exercise tolerance in patients.
References
Shen J, Wang D, Wang Z, et al., 2025, The Efficacy of Trimetazidine Combined with Clopidogrel in Treating Patients with Coronary Heart Disease and Angina Pectoris and its Impact on the Expression of cTnI, CK-MB, and NT-proBNP. Chinese Journal of Hospital Pharmacy, 25(7): 835–838.
Zhao T, Ren Y, Cheng T, 2025, The Impact of Hyperbaric Oxygen Combined with Atorvastatin Treatment on Vascular Endothelial Function, Coagulation Function, and Inflammatory Response in patients with Coronary Heart Disease After PCI. Chinese Journal of Nautical Medicine and Hyperbaric Medicine, 32(3): 271–276.
Lin Z, Tu Y, Teng Z, et al., 2024, A Randomized Controlled Study on the Treatment of Cardiac Dysfunction after Percutaneous Coronary Intervention in Patients with Coronary Heart Disease using Kuanxiong Aerosol. Chinese Journal of Integrated Traditional and Western Medicine, 44(12): 1431–1436.
Chinese Medical Association, Journal Office of Chinese Medical Association, General Practice Branch of Chinese Medical Association, et al., 2021, Guidelines for Primary Care of Stable Coronary Artery Disease (2020). Chinese Journal of General Practitioners, 20(3): 265–273.
Zhang Y, Nie Y, 2023, A Comparative Study on the Impact of Bisoprolol Fumarate and Freeze-Dried Recombinant Human Brain Natriuretic Peptide on Cardiac Function Recovery in Patients with Coronary Heart Disease Undergoing PCI. Journal of Health Medicine Research and Practice, 20(4): 21–24.
Zhang H, Zhang H, Xu X, et al., 2023, Clinical Study on the Treatment of Stable Angina Pectoris with Yinzhan Xinmai Dripping Pills Combined with Bisoprolol. Modern Drugs & Clinical Practices, 38(3): 630–634.
Liang H, Li Z, Chen X, et al., 2025, Clinical Observation on the Treatment of Coronary Heart Disease Complicated with Paroxysmal Atrial Fibrillation (Syndrome of Phlegm-Fire Disturbing the Heart) with Modified Huanglian Wendan Decoction Combined with Rivaroxaban. Journal of Emergency in Traditional Chinese Medicine, 34(6): 1046–1050.
Ma L, Shi R, He J, et al., 2025, Efficacy of Different Doses of Rivaroxaban Combined with Rosuvastatin in Patients with Atrial Fibrillation Complicated with Coronary Heart Disease. Chinese Journal of Drug Application and Monitoring, 22(5): 934–937.
Liu Y, Li Y, Zhou T, et al., 2025, Analysis of the Efficacy and Safety of Clopidogrel Combined with Rivaroxaban and Aspirin in Elderly Patients with Coronary Heart Disease Complicated with Gastrointestinal Diseases. Journal of Clinical Military Medicine, 53(8): 785–790.
Shang Z, Xu Y, 2024, Therapeutic Effect of Rivaroxaban Combined with Indobufen on Patients with Atrial Fibrillation Complicated with Coronary Heart Disease. Journal of Cardiovascular Rehabilitation Medicine, 33(6): 674–678.